Author + information
- Alexandra Arias-Mendoza,
- Leopoldo Bueno-Ayala,
- Jose Briseño-de la Cruz,
- Julio Sandoval-Zarate,
- Hector Gonzalez-Pacheco and
- Carlos Martinez-Sanchez
Copeptin, the C-terminal part of the arginine vasopressin precursor peptide, has been proposed as a marker of severity and outcome of several critical illnesses. The purpose of this investigation is to assess the diagnostic capability of Copeptin in the early diagnosis of acute coronary syndromes.
We studied fifty-one consecutive patients admitted to the emergency department with chest pain suggestive of ischemic heart disease of < 6 hours of duration and a normal electrocardiogram. Copeptin and troponin I levels were determined on admission and after 3 hours. Copeptin levels were measured using a commercially available immunoassay.
Of the 51 patients enrolled, 22 (43%) were diagnosed with an acute myocardial infarction (AMI). At the 3 hours measurement, Copeptin had a sensitivity of 97% and a specificity of 86% with a negative predictive value (NPV) of 96%. For troponin I, the sensitivity was 39%, and specificity of 89% with a NPV of 66%.
Copeptin appears to be a better marker than troponin I to exclude the diagnosis of an AMI.
Poster Sessions, Expo North
Sunday, March 10, 2013, 3:45 p.m.-4:30 p.m.
Session Title: The Blood Tells a Story: Coeptin, Fatty Acid Binding Protein, NT-Pro BNP and More
Abstract Category: 1. Acute Coronary Syndromes: Clinical
Presentation Number: 1259-207
- 2013 American College of Cardiology Foundation